Visionary: Silke Mader has a vision for the care of premature infants and their parents

For some people, experiences of profound hardship can be the beginning of the end. Others do their best to cope and move on. A small percentage of people take their difficult experience and use it to change the world. Silke Mader, Chairwoman and co-founder of the European Foundation for the Care of Newborn Infants (EFCNI), is one such person.

Twenty-two years ago, Ms. Mader gave birth to twins, a boy and a girl, at only 25 weeks. Her baby girl died but her son Lukas survived, and was admitted to the neonatology intensive care unit, where he had to stay for several months. One …

/by

Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

  • The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally
     
  • A newly formed sub-Saharan Africa unit will deploy innovative approaches to increase patient reach across the full income pyramid
     
  • Novartis is building on its established activities in malaria, cancer, sickle cell and cardiovascular diseases as well as proven social business models on the continent
     
  • A quarter of …
/by

Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  • Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting
  • US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modeling significant cost savings for health systems
  • Sandoz is the pioneer and a global leader in biosimilars, with eight approved biosimilars worldwide and more than 10 in the pipeline

Holzkirchen, November 12, 2019 – Sandoz, a Novartis division and a global …

/by

New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis

  • 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1]
     
  • PREVENT is the largest ever study of a biologic in patients with nr-axSpA and underscores Novartis leadership in rheumatology[1]
     
  • There are approximately 1.7 million patients with nr-axSpA in the EU and US[2]
     
  • PREVENT adds to 5-year evidence in ankylosing spondylitis (AS) and is a step forward in providing patients with …
/by